The present specification provides a heterocyclic compound represented by Chemical Formula 1, an organic light emitting device including the same, and a composition for an organic material layer of the organic light emitting device.

An organic light emitting diode (OLED) includes at least one emitting material layer (EML) disposed between two electrodes and including a first compound of a pyrimidine-based organic compound substituted with at least one electron-withdrawing group and a second compound of an organic compound having a tetracene-based core. The OLED can be included in an organic light emitting device. The first compound and the second compound can be the same emitting material layer or adjacently disposed emitting material layers. The OLED can lower its driving voltage and improve its luminous efficiency utilizing the advantages of the first and second compounds by adjusting energy levels between the first and second compounds.

An organic light emitting diode (OLED) includes at least one emitting material layer (EML) disposed between two electrodes and including a first compound of a pyrimidine-based organic compound substituted with at least one electron-withdrawing group and a second compound of an organic compound having a tetracene-based core. The OLED can be included in an organic light emitting device. The first compound and the second compound can be the same emitting material layer or adjacently disposed emitting material layers. The OLED can lower its driving voltage and improve its luminous efficiency utilizing the advantages of the first and second compounds by adjusting energy levels between the first and second compounds.

A condensed cyclic compound represented by Formula 1:

##STR00001## wherein in Formula 1, Ar and R.sub.1 to R.sub.8 are the same as described in the specification.

A condensed cyclic compound represented by Formula 1:

##STR00001## wherein in Formula 1, Ar and R.sub.1 to R.sub.8 are the same as described in the specification.

A compound represented by formula (I), a material for an organic electroluminescence device having the specific compound, an organic electroluminescence device of the specific compound, an electronic equipment having the organic electroluminescence device and the use of the compound of formula (I) in an organic electroluminescence device, where in formula (I), R.sup.1 and R.sup.1′ each independently represent a C.sub.1 to C.sub.6 alkyl group; R.sup.2 represents a substituted or unsubstituted C.sub.6 to C.sub.24 aryl group, a substituted or unsubstituted heteroaryl group having 3 to 9 carbon atoms, or CN; L represents a substituted or unsubstituted C.sub.6 to C.sub.40 arylene group; m is 0 to 5; and n is 1, 2 or 3:

##STR00001##

A compound represented by formula (I), a material for an organic electroluminescence device having the specific compound, an organic electroluminescence device of the specific compound, an electronic equipment having the organic electroluminescence device and the use of the compound of formula (I) in an organic electroluminescence device, where in formula (I), R.sup.1 and R.sup.1′ each independently represent a C.sub.1 to C.sub.6 alkyl group; R.sup.2 represents a substituted or unsubstituted C.sub.6 to C.sub.24 aryl group, a substituted or unsubstituted heteroaryl group having 3 to 9 carbon atoms, or CN; L represents a substituted or unsubstituted C.sub.6 to C.sub.40 arylene group; m is 0 to 5; and n is 1, 2 or 3:

##STR00001##

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),

##STR00001##

that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.

A compound represented by the formula (I):

##STR00001##

wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.